Expression profile-dependent improvement of insulin sensitivity by gene delivery of interleukin-6 in a mouse model of type II diabetes

Molecular Pharmaceutics

Volumn 10, Issue 10, 2013, Pages 3812-3821

  Mukumoto, Hanae ^a   Takahashi, Yuki ^a   Ando, Mitsuru ^a   Nishikawa, Makiya ^a   Takakura, Yoshinobu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

IL 6; Insulin resistance; Liver; Plasmid DNA; Skeletal muscle

Indexed keywords

AMYLOID A PROTEIN; CHOLESTEROL; GLUCOSE; INSULIN; INTERLEUKIN 6; MESSENGER RNA; PLASMID DNA; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BODY FAT; BODY WEIGHT; CONTROLLED STUDY; DIABETIC OBESITY; DRUG BLOOD LEVEL; DRUG EFFECT; ELECTROPORATION; EPIDIDYMIS FAT; EXPERIMENTAL MODEL; FOOD INTAKE; GENE DELIVERY SYSTEM; GENE EXPRESSION PROFILING; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HYDRODYNAMICS BASED TRANSFECTION; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; INTERMETHOD COMPARISON; LIVER; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; TRANSIENT EXPRESSION;

ANIMALS; DIABETES MELLITUS, TYPE 2; INSULIN RESISTANCE; INTERLEUKIN-6; LIVER; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84888377946     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400288e     Document Type: Article

References (30)

1. Nathan, D. M.; Buse, J. B.; Davidson, M. B.; Ferrannini, E.; Holman, R. R.; Sherwin, R.; Zinman, B. Medical management of hyperglycaemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009, 52, 17-30.
2. Wagner, H.; Degerblad, M.; Thorell, A.; Nygren, J.; Stähle, A.; Kuhl, J.; Brismar, T. B.; Öhrvik, J.; Efendic, S.; Bävenholm, P. N. Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes. Diabetes Care 2006, 29, 1471-1477.
3. Tufescu, A.; Kanazawa, M.; Ishida, A.; Lu, H.; Sasaki, Y.; Ootaka, T.; Sato, T.; Kohzuki, M. Combination of exercise and losartan enhances renoprotective and peripheral effects in spontaneously type 2 diabetes mellitus rats with nephropathy. J. Hypertens. 2008, 26, 312. 321.
4. Febbraio, M. A.; Pedersen, B. K. Muscle-derived interleukin-6: Mechanisms for activation and possible biological roles. FASEB J. 2002, 16, 1335-1347.
5. Pedersen, B. K.; Febbraio, M. A. Muscle as an endocrine organ: Focus on muscle-derived interleukin-6. Physiol. Rev. 2008, 88, 1379. 1406.
6. Helge, J. W.; Stallknecht, B.; Pedersen, B. K.; Galbo, H.; Kiens, B.; Richter, E. A. The effect of graded exercise of IL-6 release and glucose uptake in human skeletal muscle. J. Physiol. 2003, 546, 299-305.
7. Carey, A. L.; Febbraio, M. A. Interleukin-6 and insulin sensitivity: Friend or foe? Diabetologia 2004, 47, 1135-1142.
8. Glund, S.; Krook, A. Role of interleukin-6 signalling in glucose and lipid metabolism. Acta Physiol. 2008, 192, 37-48.
9. Tsigos, C.; Papanicolaou, D. A.; Kyrou, I.; Defensor, R.; Mitsiadis, C. S.; Chrousos, G. P. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J. Clin. Endocrinol. Metab. 1997, 82, 4167-4170.
10. Féve, B.; Bastard, J. P. The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2009, 5, 305-311.
11. Wallenius, V.; Wallenius, K.; Ahrén, B.; Rudling, M.; Carlsten, H.; Dickson, S. L.; Ohlsson, C.; Jansson, J. O. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 2002, 8, 75-79.
12. Fosgerau, K.; Galle, P.; Hansen, T.; Albrechtsen, A.; De Lemos Rieper, C.; Pedersen, B. K.; Larsen, L. K.; Thomsen, A. R.; Pedersen, O.; Hansen, M. B.; Steensberg, A. Interleukin-6 autoantibodies are involved in the pathogenesis of a subset of type 2 diabetes. J. Endocrinol. 2010, 204, 265-273.
13. Sadagurski, M.; Norquay, L.; Farhang, J.; D'Aquino, K.; Copps, K.; White, M. F. Human IL6 enhances leptin action in mice. Diabetologia 2010, 53, 525-535.
14. Franckhauser, S.; Elias, I.; Rotter Sopasakis, V.; Ferré, T.; Nagaev, I.; Andersson, C. X.; Agudo, J.; Ruberte, J.; Bosch, F.; Smith, U. Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. Diabetologia 2008, 51, 1306. 1316.
15. Klover, P. J.; Zimmers, T. A.; Koniaris, L. G.; Mooney, R. A. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003, 52, 2784-2789.
16. Senn, J. J.; Klover, P. J.; Nowak, I. A.; Mooney, R. A. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002, 51, 3391-3399.
17. Senn, J. J.; Klover, P. J.; Nowak, I. A.; Zimmers, T. A.; Koniaris, L. G.; Furlanetto, R. W.; Mooney, R. A. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J. Biol. Chem. 2003, 278, 13740. 13746.
18. Inoue, H.; Ogawa, W.; Asakawa, A.; Okamoto, Y.; Nishizawa, A.; Matsumoto, M.; Teshigawara, K.; Matsuki, Y.; Watanabe, E.; Hiramatsu, R.; Notohara, K.; Katayose, K.; Okamura, H.; Kahn, C. R.; Noda, T.; Takeda, K.; Akira, S.; Inui, A.; Kasuga, M. Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab. 2006, 3, 267-275.
19. Weigert, C.; Hennige, A. M.; Lehmann, R.; Brodbeck, K.; Baumgartner, F.; Schaüble, M.; Häring, H. U.; Schleicher, E. D. Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. J. Biol. Chem. 2006, 281, 7060-7067.
20. Nieto-Vazquez, I.; Fernandez-Veledo, S.; De Alvaro, C.; Lorenzo, M. Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes 2008, 57, 3211-3221.
21. Al-Khalili, L.; Bouzakri, K.; Glund, S.; Lönnqvist, F.; Koistinen, H. A.; Krook, A. Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol. Endocrinol. 2006, 20, 3364-3375.
22. Mennuni, C.; Calvaruso, F.; Zampaglione, I.; Rizzuto, G.; Rinaudo, D.; Dammassa, E.; Ciliberto, G.; Fattori, E.; La Monica, N. Hyaluronidase increases electrogene transfer efficiency in skeletal muscle. Hum. Gene Ther. 2002, 13, 355-365.
23. Liu, F.; Song, Y. K.; Liu, D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 1999, 6, 1258-1266.
24. Mitsui, M.; Nishikawa, M.; Zang, L.; Ando, M.; Hattori, K.; Takahashi, Y.; Watanabe, Y.; Takakura, Y. Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression. J. Gene Med. 2009, 11, 435-443.
25. Hattori, K.; Nishikawa, M.; Watcharanurak, K.; Ikoma, A.; Kabashima, K.; Toyota, H.; Takahashi, Y.; Takahashi, R.; Watanabe, Y.; Takakura, Y. Sustained exogenous expression of therapeutic levels of IFN-γ ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization. J. Immunol. 2010, 184, 2729-2735.
26. Yamaoka, K.; Nakagawa, T.; Uno, T. Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm. 1978, 6, 547-558.
27. Wallenius, K.; Wallenius, V.; Sunter, D.; Dickson, S. L.; Jansson, J. O. Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem. Biophys. Res. Commun. 2002, 293, 560-565.
28. Matthews, V. B.; Allen, T. L.; Risis, S.; Chan, M. H. S.; Henstridge, D. C.; Watson, N.; Zaffino, L. A.; Babb, J. R.; Boon, J.; Meikle, P. J.; Jowett, J. B.; Watt, M. J.; Jansson, J. O.; Bruce, C. R.; Febbraio, M. A. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 2010, 53, 2431-2441.
29. Ellingsgaard, H.; Hauselmann, I.; Schuler, B.; Habib, A. M.; Baggio, L. L.; Meier, D. T.; Eppler, E.; Bouzakri, K.; Wueest, S.; Muller, Y. D.; Hansen, A. M. K.; Reinecke, M.; Konrad, D.; Gassmann, M.; Reimann, F.; Halban, P. A.; Gromada, J.; Drucker, D. J.; Gribble, F. M.; Ehses, J. A.; Donath, M. Y. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat. Med. 2011, 17, 1481-1489.
30. Straub, R. H. Evolutionary medicine and chronic inflammatory state-known and new concepts in pathophysiology. J. Mol. Med. 2012, 90, 523-534.